Abstract
The aim of this study was to evaluate the medium-term effects of the selective AT1-blocker irbesartan on atrial natriuretic peptide (ANP) levels in patients with moderate essential hypertension. The drug was given orally in a daily dose of 300 mg for 30 days. Plasma ANP levels increased by 15.7% despite the drop in blood pressure and the slight decrease of atrial and ventricular diameters. These findings indicate that AT,-blockers like irbesartan exert part of their antihypertensive action by increasing ANP plasma levels.
Publication types
-
Clinical Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Angiotensin Receptor Antagonists*
-
Antihypertensive Agents / therapeutic use*
-
Atrial Natriuretic Factor / blood*
-
Biphenyl Compounds / therapeutic use*
-
Blood Pressure / drug effects
-
Humans
-
Hypertension / blood*
-
Hypertension / drug therapy*
-
Hypertension / physiopathology
-
Irbesartan
-
Male
-
Middle Aged
-
Receptor, Angiotensin, Type 1
-
Tetrazoles / therapeutic use*
Substances
-
Angiotensin Receptor Antagonists
-
Antihypertensive Agents
-
Biphenyl Compounds
-
Receptor, Angiotensin, Type 1
-
Tetrazoles
-
Atrial Natriuretic Factor
-
Irbesartan